- GILD, GIS Ticker
- 🇩🇪 XETRA, 🇩🇪 F, 🇺🇸 NASDAQ Exchange
- 11,000 Employees
- 💊 Health Care Sector
- 🧪 Biotechnology Industry
- Daniel O'Day CEO
Financial statements — Gilead Sciences
The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Total Revenue |
|
25B | 22B | 22B | 26B | 30B |
| Cost Of Revenue |
|
4.6B | 4.7B | 4.9B | 4.4B | 4.3B |
| Gross Profit |
|
20B | 18B | 17B | 22B | 26B |
| Research and Development |
|
5B | 9.1B | 5B | 3.7B | 5.1B |
| Selling General and Admin |
|
5.2B | 4.4B | 4.1B | 3.9B | 3.4B |
| Operating Expense |
|
21B | 18B | 14B | 12B | 13B |
| Operating Income |
|
4.1B | 4.3B | 8.2B | 14B | 18B |
| Other Income Expense Net |
|
0 | 0 | 0 | 0 | 0 |
| EBIT |
|
4.1B | 4.3B | 8.2B | 14B | 18B |
| Interest Income |
|
980M | 1M | 1.1B | 1.1B | 960M |
| Pretax Income |
|
1.7B | 5.2B | 7.8B | 14B | 17B |
| Income Tax |
|
1.6B | -200M | 2.3B | 8.9B | 3.6B |
| Minority Interest |
|
-34M | -22M | 5M | 16M | -13M |
| Net Income |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| Net Income Basic |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Current cash |
|
7.4B | 24B | 31B | 26B | 12B |
| Short term investments |
|
2B | 1.4B | 740M | 1B | 1.6B |
| Receivables |
|
4.9B | 3.6B | 3.3B | 3.9B | 4.5B |
| Inventory |
|
1.7B | 920M | 810M | 800M | 1.6B |
| Other current assets |
|
2B | 1.4B | 740M | 1B | 1.6B |
| Current assets |
|
16B | 30B | 36B | 32B | 20B |
| Long term investments |
|
52B | 31B | 28B | 38B | 37B |
| Property plant equipment |
|
5B | 4.5B | 4B | 3.3B | 2.9B |
| Goodwill |
|
8.1B | 4.1B | 4.1B | 4.2B | 1.2B |
| Intangible assets |
|
33B | 14B | 16B | 17B | 9B |
| Other assets |
|
5.5B | 7.4B | 2.6B | 2.7B | 2.6B |
| Total assets |
|
68B | 62B | 64B | 70B | 57B |
| Accounts payable |
|
840M | 710M | 790M | 810M | 1.2B |
| Current long term debt |
|
2.8B | 2.5B | 2.7B | 0 | 0 |
| Other current liabilities |
|
7.8B | 6.5B | 7.1B | 11B | 8B |
| Total current liabilities |
|
11B | 9.8B | 11B | 12B | 9.2B |
| Long term debt |
|
29B | 22B | 25B | 31B | 26B |
| Other liabilities |
|
10B | 7.1B | 7B | 7.4B | 2B |
| Minority Interest |
|
19M | 130M | 150M | 59M | 480M |
| Total Liabilities |
|
50B | 39B | 42B | 50B | 38B |
| Common stock |
|
1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Retained earning |
|
14B | 19B | 19B | 19B | 18B |
| Treasury stock |
|
0 | 0 | 0 | 0 | 0 |
| Capital surplus |
|
• | • | • | • | • |
| Shareholder equity |
|
18B | 23B | 21B | 20B | 19B |
| Net tangible assets |
|
-23B | 4.6B | 1.5B | -820M | 8.7B |
| 20 ← 16 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
| Net Income |
|
120M | 5.4B | 5.5B | 4.6B | 14B |
| Depreciation |
|
1.5B | 1.4B | 1.4B | 1.3B | 1.2B |
| Changes in receivables |
|
1.3B | 260M | -520M | -660M | -1.3B |
| Changes in inventories |
|
760M | 110M | 13M | -790M | -370M |
| Cash change |
|
-17B | -6.6B | 4.8B | 14B | -2.7B |
| Cash flow |
|
8.2B | 9.1B | 8.4B | 12B | 17B |
| Capital expenditures |
|
-650M | -830M | -920M | -590M | -750M |
| Investments |
|
• | • | • | • | • |
| Investing activity other |
|
• | • | • | • | • |
| Total investing cash flows |
|
-15B | -7.8B | 14B | -16B | -12B |
| Dividends paid |
|
3.4B | • | • | • | • |
| Net borrowings |
|
22B | -1.2B | -4.4B | 3.6B | 13B |
| Other financing cash flows |
|
• | • | • | • | • |
| Cash flow financing |
|
770M | -7.6B | -12B | 3.4B | -9.3B |
| Exchange rate effect |
|
• | • | • | • | • |
It develops and implements innovative methods of treatment and prevention of severe diseases. The main research focuses on the fight against HIV and AIDS, cancer, hepatitis B and C, that is, specializes mainly in antiviral drugs. New types of treatments for Hematology, liver diseases, inflammatory and infectious diseases are also being produced, including various types of flu virus, including Harvoni and Sovaldi. In addition to the therapeutic direction, systems of specific care for patients with a severe form of the disease are being developed. Serial production of new drugs is concentrated in the regions where the problem of the spread of deadly diseases is most urgent - North and South Africa, Europe, and Asia.
The founder of the company, tried to «recruit» Warren Buffett as an investor and a member of the Board of Directors, but was unsuccessful. A year ago, The Times reported that this «American pharmaceutical firm used a controversial tax loophole to shift almost 20 billion euros of profits through an Irish legal entity in just two years.»